In a paper published in the Journal of Clinical Oncology, medical oncologists have delineated their recommendations to improve cancer care and provide better access to quality care for those patients with financial issues and on Medicaid.
In a paper published in the Journal of Clinical Oncology, medical oncologists have delineated their recommendations to improve cancer care and provide better access to quality care for those patients with financial issues and on Medicaid. Based on the principles that Medicaid patients should have equal access to high-quality cancer care delivered by cancer specialists, as do patients on private insurance, the committee formulated several policy recommendations. Some key points include:
Medicaid reform has been a topic of debate for a long time, and the authors think that post-ACA, the disparities in cancer care will worsen. The authors emphasize that while Medicaid is fraught with a million faults, and healthcare providers and their financial administrators do not favor Medicaid’s low reimbursement rates compared to Medicare, we have to accept that Medicaid is the lifeline for patients. The only option, therefore, is for all stakeholders to contribute their voice to the discussion—provide their thoughts and recommendations, as did ASCO, to help reform care delivery so it’s a win-win for both the patient and the oncology care provider.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More